Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.85
- Piotroski Score 1.00
- Grade Neutral
- Symbol (RETA)
- Company Reata Pharmaceuticals, Inc.
- Price $172.36
- Changes Percentage (0.02%)
- Change $0.04
- Day Low $172.32
- Day High $172.46
- Year High $172.46
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2023
- Fiscal Year End N/A
- Average Stock Price Target $46.00
- High Stock Price Target $115.00
- Low Stock Price Target $27.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.60
- Trailing P/E Ratio -66.292307692308
- Forward P/E Ratio -66.292307692308
- P/E Growth -66.292307692308
- Net Income $-311,901,000
Income Statement
Quarterly
Annual
Latest News of RETA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Indian Billionaire Yusuff Ali's Lulu Retail Raises Size Of Abu Dhabi IPO To $1.7 Billion
Lulu Retail Holdings, a hypermarket chain in the Middle East founded by Indian billionaire M.A. Yusuff Ali, plans to raise $1.7 billion in its IPO by increasing shares to 3.1 billion....
By Forbes | 5 hours ago -
Republicans hope to retain 3 open Indiana House seats and target another long held by Democrats
Republicans in Indiana aim to retain three congressional seats without incumbents running and defeat an incumbent Democrat. Hotly contested primaries occurred in spring due to vacancies. The GOP targe...
By AP NEWS | 8 hours ago -
Pennsylvania's election will be "fair, safe and secure," secretary of commonwealth says
Pennsylvania's Secretary of the Commonwealth, Al Schmidt, assures voters of a free, fair, safe, and secure election. With 2 million mail-in ballots, results may not be final on Election Night due to s...
By CBS News | 10 hours ago